Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modulating chemicals.

The Estée Lauder Companies and Atropos Therapeutics are joining forces to discover botanical senomodulators or senescence-modulating chemicals.

Atropos Therapeutics Inc. has a proprietary platform to identify and develop senescence-modulating chemicals.

"Partnering with The Estée Lauder Companies, a leader in global prestige beauty that uses natural products nicely complements our pipeline efforts to identify senomodulating chemicals by high content screening and using AI based drug design to interfere with activities necessary for geroconversion and senescence.  With the three pipelines open, Atropos can move to the next stage of its development with isolated molecules in hand," says  Andrew Koff, Founder of Atropos Therapeutics.

Tom Mammone, Vice President of Skin Physiology and Pharmacology at The Estée Lauder Companies is excited by this unique opportunity as well.  "Atropos' in-depth understanding of and its unique and well-validated approaches to identify senescence modulators will synergize well with our expertise in the natural product space.  Botanically derived senosuppressors are not only sure to be interesting new molecules--the utilization of such will have great commercial potential for us."